Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
SARS
Research from National Institutes of Health in the area of SARS published
October 15th, 2008
According to recent research published in the Journal of Virology, "The immunogenicity and protective efficacy of a live attenuated vaccine consisting of a recombinant severe acute respiratory syndrome (SARS) coronavirus lacking the E gene (rSARS-CoV-Delta E) were studied using hamsters." "Hamsters immunized with rSARS-CoV-Delta E developed high serum-neutralizing antibody titers and were protected from replication of homologous (SARS-CoV Urbani) and heterologous (GD03) SARS-CoV in the upper and lower respiratory tract. rSARS-CoV-Delta E-immunized hamsters remained active following wildtype virus challenge, while mock-immunized hamsters displayed decreased...
Source: Vaccine Weekly (2008-10-15)
|
